Cellebrite DI (NASDAQ:CLBT) Hits New 1-Year Low After Insider Selling

Cellebrite DI Ltd. (NASDAQ:CLBT)’s stock price reached a new 52-week low during trading on Thursday after an insider sold shares in the company. The company traded as low as $10.55 and last traded at $10.1960, with a volume of 908842 shares trading hands. The stock had previously closed at $15.25.

Specifically, CEO Thomas E. Hogan sold 139,713 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer directly owned 790,548 shares in the company, valued at approximately $12,166,533.72. The trade was a 15.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Needham & Company LLC cut their price target on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday. Lake Street Capital decreased their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings cut Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday. JPMorgan Chase & Co. cut their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday. Finally, DA Davidson reduced their target price on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a report on Friday. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and an average price target of $16.70.

Cellebrite DI News Summary

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Cellebrite DI Price Performance

The stock has a market cap of $2.78 billion, a PE ratio of 50.64, a price-to-earnings-growth ratio of 1.34 and a beta of 1.18. The stock has a 50-day moving average price of $14.47 and a two-hundred day moving average price of $14.03.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.05. The company had revenue of $131.14 million for the quarter, compared to analysts’ expectations of $131.50 million. Cellebrite DI had a net margin of 11.43% and a return on equity of 16.04%. Equities research analysts expect that Cellebrite DI Ltd. will post 0.41 earnings per share for the current year.

Institutional Trading of Cellebrite DI

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cooper Creek Partners Management LLC purchased a new position in Cellebrite DI during the 3rd quarter worth $55,999,000. Capital International Investors bought a new position in shares of Cellebrite DI during the 4th quarter worth $41,073,000. Invesco Ltd. increased its stake in shares of Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after buying an additional 2,054,644 shares during the period. Weiss Asset Management LP raised its holdings in shares of Cellebrite DI by 3,485.3% in the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after acquiring an additional 1,846,851 shares in the last quarter. Finally, Artisan Partners Limited Partnership bought a new stake in shares of Cellebrite DI in the fourth quarter valued at about $25,871,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.